Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: AI
Barbados recently joined the list of 26 countries and territories that have been certified by the World Health Organization for eliminating mother-to-child-transmission (EMTCT) of HIV, syphilis or hepatitis B. 15 of these countries are in the Americas, which makes the region a global leader to achieve this feat.
The major public health milestone comes after years of sustained efforts to prevent mother-to-child-transmission of HIV.
Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said, “I congratulate Barbados on protecting a generation of children from HIV,” said “Barbados has shown what universal health coverage looks like in practice: free services for every pregnant woman, regardless of nationality, and care that respects her rights and privacy. With 15 countries and territories in the Americas now recognized, the region continues to show the world the way.”
The Caribbean country's achievement was backed by widespread coverage of antenatal care, HIV testing and antiretroviral treatment.
“Barbados has shown that eliminating mother-to-child transmission of HIV is possible when women and children have access to quality health services without barriers,” said Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO) and WHO Regional Director for the Americas.
“This achievement means that children are born free of HIV and that women living with HIV can access the care and treatment they need. It is a proud moment for Barbados, the Caribbean, and the global effort to end AIDS in children.”
During the three-year period, 98% of pregnant women received antenatal care, 98% were tested for HIV, and 98% of pregnant women living with HIV received antiretroviral treatment.
An essential step in Barbados' HIV elimination strategy is making HIV testing and treatment accessible to all pregnant women. Free HIV testing and treatment are available to all pregnant women regardless of race and nationality. These services are available through public clinics and hospitals.
“This is incredible for us, and it allows us to be able to see our children living their full, best lives. It allows mothers to be able to have the benefit of treatment during pregnancy, before treatment, but also, it means that we're able to ensure that we have a healthier population, and we're able to join the other countries around the globe that have also equally been able to achieve this historic milestone,” said Lisa Cummins, Minister of Health and Wellness of Barbados.
Additionally, pregnant women are offered voluntary and confidential HIV testing. Those who test positive are provided specialised care and treatment to reduce the risk of passing the virus to their babies.
Antiretroviral therapy (ART) is central to preventing mother-to-child HIV transmission. These medicines suppress HIV in the body, reducing the amount of virus in the blood. When an HIV+ pregnant woman receives ART, the risk of transmission to her baby can be reduced significantly.
Barbados also provides early testing and follow-up care for babies at risk of contracting HIV from their mothers.
Also read: 1 In 60 Adults In Fiji May Now Have HIV As Meth Use, Unsafe Injecting And Treatment Gaps Fuel Surge
HIV can be transmitted from a woman living with HIV to her child during pregnancy, childbirth or breastfeeding. This is known as vertical transmission or mother-to-child transmission.
Without preventive interventions, the risk of transmission can be significant. However, timely diagnosis, antiretroviral treatment during pregnancy and appropriate care around childbirth can substantially reduce this risk.
With effective treatment and appropriate medical support, women living with HIV can have children who are born without the infection.
The WHO certification recognises that Barbados has brought transmission down to a level at which it is no longer considered a public health problem. It does not mean that HIV has been eliminated from the country.
Credit: Radical Numerics
In a world first, scientists have administered AI-designed viruses to a human patient to treat a serious antibiotic-resistant bacterial infection. The experimental treatment marks a milestone in the development of personalized therapies that use artificial intelligence (AI) to design viruses capable of targeting drug-resistant bacteria.
California-based AI startup Radical Numerics announced the development in a blog post, saying a patient with a serious bacterial infection received an experimental treatment containing viruses generated by its AI model, Omnii-1.
Also read: AI Creates 16 Viruses To Kill Drug-Resistant E. coli, Raises Biosafety Concerns
The treatment uses bacteriophages, or phages, which are viruses that infect and kill bacteria. Phage therapy is being explored as an alternative when antibiotics fail, particularly in drug-resistant infections.
However, identifying phages that can effectively target the specific bacteria causing an individual patient's infection remains a major challenge.
Antibiotic resistance is a growing global health threat. A 2024 study published in The Lancet projected that bacterial antimicrobial resistance could directly cause 39.1 million deaths globally between 2025 and 2050.
Radical Numerics said it trained Omnii-1, its multimodal genome language model, to address the challenge of identifying and designing effective phages.
"We trained Omnii-1, our multimodal genome language model, to help bridge this gap. We demonstrate that it can generate viable phages, prioritize variants, and predict phage-host interactions," the company said.
"In the world's first clinical use of AI-generated phages, Omnii-1 designs were administered to a human patient under compassionate use," it added.
Read More: Anthropic Says Claude Blocked Bird Flu, Chikungunya Research: How AI Could Enable Biological Misuse
According to the company, researchers tested the AI-designed viruses against bacteria obtained from the patient before administering the treatment. The resulting phage cocktail eliminated the patient's antibiotic-resistant bacterial sample in laboratory testing.
The treatment was administered under an authorized, physician-led compassionate-use pathway. Compassionate use allows patients with serious conditions to access investigational treatments outside clinical trials when satisfactory alternatives are unavailable, subject to regulatory authorization and appropriate oversight.
The report has not been peer-reviewed or published in a scientific journal. Company officials said the trial had been authorized by the Food and Drug Administration, the New York Times reported.
The company has not disclosed the patient's diagnosis, clinical course or treatment outcome, citing privacy concerns. It is therefore unclear whether the treatment successfully cleared the infection.
Eric Nguyen, chief executive officer of Radical Numerics, said the company was prioritizing patient confidentiality and intended to publish its findings through peer-reviewed research.
"We intend to publish our scientific findings through peer-reviewed research, with any future disclosure of clinical details subject to appropriate consent," he added.
The company said making phage therapy accessible to more patients would require reliable workflows for designing effective phages against individual bacterial infections.
The development comes amid growing interest in using AI to accelerate medical research, including the design of new biological therapies.
In August 2026, researchers at Stanford University and the Arc Institute announced that they had used AI to design previously unseen bacteriophages capable of killing E. coli bacteria in laboratory experiments.
Of nearly 300 AI-designed phages synthesized and tested, 16 produced functional viruses. However, these experiments were conducted in bacteria and did not involve human patients.
The Radical Numerics development goes a step further by reporting the clinical administration of AI-designed phages to a human patient.
Credit: iStock
The share of US children aged 5–17 who had ever received an attention-deficit/hyperactivity disorder (ADHD) diagnosis increased from 9.9% in 2019 to 13.8% in 2025, according to new CDC data.
Nearly 1 in 7 children and adolescents aged 5–17 in the US have received an ADHD diagnosis, according to a QuickStats report published in the CDC's latest Morbidity and Mortality Weekly Report (MMWR).
The National Center for Health Statistics (NCHS) found that the percentage of children who had ever been diagnosed with ADHD increased by 3.9 percentage points over the seven years, representing a relative rise of approximately 39%.
More boys received the diagnoses than girls throughout the period, although the trends fluctuated from year to year.
Also read: ADHD Linked To 71% Higher Risk Of Death; Suicide And Injuries Among Top Concerns
According to the CDC data, the percentage of US children and adolescents aged 5–17 who had ever received an ADHD diagnosis rose from 9.9% in 2019 to 11.6% in 2020. It dipped to 10.8% in 2021 before increasing to 11.5% in 2022.
The figure climbed to 13.4% in 2023, 13.6% in 2024 and 13.8% in 2025.
Among boys, the percentage increased from 13.2% in 2019 to 17.5% in 2025, reaching a high of 17.6% in 2024.
Among girls, it rose from 6.5% in 2019 to 9.9% in 2025, although it dipped from 9.9% in 2023 to 9.3% in 2024.
The estimates are based on household interviews with a sample of the civilian, noninstitutionalised US population. The survey considered children to have an ADHD diagnosis if a parent or respondent answered yes to whether a doctor or health professional had ever told them the child had ADHD or attention-deficit disorder (ADD).

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects attention, executive function, impulse control and activity levels. It typically begins in childhood, with symptoms appearing before age 12, and can persist into adulthood.
Read More: Attention Deficit May Be The Wrong Way To Understand ADHD, Says US Psychiatrist
According to the National Institute of Mental Health (NIMH), ADHD symptoms fall into two primary categories:
The American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends that primary care clinicians initiate an ADHD evaluation for children and adolescents aged 4–18 who present with academic or behavioural problems and symptoms of inattention, hyperactivity or impulsivity.
The guideline recommends assessing children using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, based on information from parents, teachers and other school personnel.
It also calls for screening for coexisting emotional, behavioural, developmental and physical conditions.
For preschool-aged children, parent training in behaviour management is recommended as a first-line approach.
For school-aged children and adolescents, the AAP recommends FDA-approved medication alongside behavioural and school-based interventions. It also emphasises managing ADHD as a chronic condition, with ongoing monitoring and follow-up.
© $2026 Times Horizon Private Limited